Financial Performance - For the year ended 31 March 2025, the Group's revenue decreased by approximately HK$100.1 million or approximately 15.5%, from approximately HK$644.6 million for the year ended 31 March 2024 to approximately HK$544.5 million[21]. - The Group recorded a profit of HK$30.4 million for the year ended 31 March 2025, compared to a loss of HK$26.5 million for the year ended 31 March 2024[21]. - The Group's revenue decreased by approximately HKD 100.1 million or 15.5% to approximately HKD 544.5 million for the fiscal year ending March 31, 2025, compared to approximately HKD 644.6 million for the previous fiscal year[26]. - The Group recorded a profit of HKD 30.4 million, a significant improvement from a loss of HKD 26.5 million in the previous fiscal year[26]. - Total comprehensive income attributable to owners of the Company was approximately HK$36.3 million for the Reporting Year, compared to a total comprehensive expense of approximately HK$22.3 million for the year ended 31 March 2024[76]. - Basic earnings per share for the year ended 31 March 2025 was approximately HK7.41 cents, compared to a basic loss per share of approximately HK4.41 cents for the year ended 31 March 2024[117]. Business Segments Performance - The Healthcare and Medicated Products Business recorded growth in both revenue and profit despite market slowdowns[22]. - The laboratory supply distribution business also experienced growth in both revenue and profit, despite challenges such as the depreciation of the Japanese yen[22]. - The Health and Medicated Food Distribution Business achieved revenue and profit growth despite market slowdowns, aided by strategic initiatives such as developing new sales channels[51]. - The IRO business maintained revenue at approximately the same level as the previous fiscal year, successfully achieving profitability when excluding other gains from the disposal of the Japan-IRO business[24]. - The In-house R&D business made steady progress in each pipeline, although overall progress fell behind the original plan, leading to a decrease in R&D expenses compared to the previous fiscal year[24]. - HCP Business recorded revenue of approximately HK$169.6 million for the Reporting Year, representing an increase of approximately 21.6% compared to approximately HK$139.5 million for the year ended 31 March 2024[58]. - The IRO Business with CRO Services and In-house R&D Business Unit recorded revenue of approximately HK$45.2 million, representing an increase of approximately 18.5% compared to approximately HK$38.1 million for the year ended 31 March 2024[70]. - The Group's garment business recorded revenue of approximately HK$329.7 million, representing a decrease of approximately 29.4% compared to approximately HK$467.0 million for the year ended 31 March 2024[72]. Strategic Initiatives - The Company has shifted its business portfolio to focus on profit-generating businesses, disposing of its Japan-IRO business and In-house R&D business during the Reporting Period[18]. - The Company aims to connect the healthcare industries of China, Japan, and the broader Asian region as a specialized trading partner[16]. - The Company is actively promoting product and business development through partnerships with startups and research institutions in China and Japan[17]. - The Group plans to strengthen and expand existing profit-generating businesses by anticipating market changes and updating product offerings[30]. - The Group aims to optimize its business portfolio by accelerating actions such as acquiring the China-IRO and HCP businesses and disposing of the Japan-IRO business[37]. - The Group is exploring new profit-generating businesses, including a partnership to enter the cosmetics sector through a minority investment made in February[38]. Operational Efficiency - The Group is committed to enhancing operational efficiency and exploring new product categories in the Laboratory Supply Distribution Business to drive growth[31]. - The Group's administrative expenses decreased by HK$14.4 million due to delays in the development progress of the In-house R&D business[76]. - Selling and distribution expenses decreased to approximately HK$35.3 million for the year ended 31 March 2025 from approximately HK$48.8 million for the year ended 31 March 2024, representing a decrease of approximately 27.7%[110]. - Research and development expenses decreased to approximately HK$18.1 million for the year ended 31 March 2025 from approximately HK$24.3 million for the year ended 31 March 2024, representing a decrease of approximately 25.5%[109]. Market Challenges - The Garment Business faced significant challenges with a notable decline in net sales due to intensified price competition and did not meet profitability expectations[26]. - The garment business faces challenges due to economic uncertainty and shifting consumer behavior, prompting a focus on cost control and operational streamlining[169]. Management and Personnel - Mr. Washikita Kenichiro joined EPS HD in April 2024, bringing over 37 years of experience in diversified business areas including apparel and medical healthcare[175]. - Mr. Miyano Tsumoru has over 34 years of experience in the domestic pharmaceutical industry in Japan, focusing on business development and marketing since joining EPS HD in January 2002[177]. - Mr. Narumi Shoichi has over 15 years of experience in pharmaceutical development and cross-border business, currently serving as deputy director of the business development office of EPS HD[181]. - Mr. Chiu Chun Tak, appointed as an executive director on November 1, 2023, has over 34 years of experience in accounting, auditing, corporate finance, and mergers and acquisitions[183]. - Ms. Du Yao, with over 13 years of experience in skincare R&D, founded Merry Plus Corporation in 2020 and BioBeaute Co., Ltd in 2024[188]. - Mr. Liang Fei has been with EPS Japan since 2004 and holds a master's degree in information engineering, contributing to the company's technological advancements[190]. - Mr. Uematsu Takahiro has over 35 years of experience in product management and investment strategy management, leading the compliance group at EPS HD since January 2002[192]. - Mr. Yan Ping was appointed as a non-executive Director effective from November 1, 2023, bringing extensive experience in the biomedical industry in the PRC[198]. - Mr. Chan Cheuk Ho has been an independent non-executive Director since July 9, 2021, and is responsible for providing independent judgment on the Group's strategy and performance[200]. Financial Position - The Group's net current assets increased to approximately HK$151.5 million as at 31 March 2025 from approximately HK$6.9 million as at 31 March 2024[124]. - The Group's current ratio increased from approximately 1.0 as at 31 March 2024 to approximately 2.9 as at 31 March 2025, mainly due to a significant decrease in current liabilities of approximately 60.9%[124]. - As of March 31, 2025, the group's debt-to-equity ratio was 0.04, compared to 0.08 as of March 31, 2024[128]. - The group has a total bank financing agreement amounting to approximately HK$7.8 million, with an unused bank financing rate of 63% as of March 31, 2025[128]. Other Information - The company has not disclosed any recent financial performance metrics or user data in the provided documents[1]. - There are no mentions of new product developments or market expansion strategies in the provided documents[1]. - The documents do not include any future outlook or performance guidance for the company[1]. - No information regarding mergers or acquisitions was found in the provided documents[1].
EPS创健科技(03860) - 2025 - 年度财报